Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. - Test2 - elhamkhani - TriplyDB

Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

http://www.wikidata.org/entity/Q39980070

about

Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy Renal and neurological side effects of colistin in critically ill patients Isolation and characterization of φkm18p, a novel lytic phage with therapeutic potential against extensively drug resistant Acinetobacter baumannii Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways.Colistin in the 21st century.A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa.Convulsions in a critically ill patient on hemodialysis: Possible role of low dose colistin Colistin dosing and nephrotoxicity in a large community teaching hospital.Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes 'Old' antibiotics for emerging multidrug-resistant bacteria Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway.Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia Colistin and polymyxin B: peas in a pod, or chalk and cheese?Rapid intelligence and failing weapons: meeting the challenges of 21st century infections in the deployed clinical environment.Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach.Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells.Melatonin attenuates colistin-induced nephrotoxicity in rats.Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing The use of intravenous colistin among children in the United States: results from a multicenter, case series Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics Colistin neurotoxicity: revisited.Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.Intravenous Colistin Use for Multidrug-Resistant Gram-Negative Infections in Pediatric Patients The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.Comment: Fundamentals and Innovation in Antibiotic Trials

P2860

Q27014993-664B32C5-2074-4611-A41E-4CD4AD2C419C Q27499294-DBEE58E6-D815-4751-A270-F6EFE640DDE4 Q28484243-4363A98F-CD64-4A1D-8539-894946656144 Q33751736-5E9E443D-A205-4A38-B446-B62F0E56B9C0 Q33798324-609E8CB4-F171-4C5E-9009-FA372A3D8451 Q33847509-00C2D107-B230-451C-AE4D-B04399071637 Q34074975-341FC915-C135-4B80-8778-308FA3C47D66 Q34124176-3FBC316C-6D8E-482E-86F8-01E70582B7E8 Q34150958-CDFCDBF0-60AA-44EB-BC95-F1DA19FDA1ED Q34320945-0A60B6CA-112A-4F00-ACA1-B8E1E84A38BC Q34565772-86CC3E00-4BF9-4E24-A72F-D8A1D28B9612 Q34596336-44B00B77-485F-439A-9DB0-583435A26C22 Q34766191-372B61E3-BAE8-4C4B-84D0-CBF72DA5E3E1 Q34922961-2D6545F2-20DA-41D9-A8EF-2C7053DF025C Q34955582-A8A95603-B547-438A-A569-ABE30D31740A Q34994417-35F452F4-9454-4799-B1D5-B70AE5E17F92 Q35008357-6910F717-2C64-40A8-ADF2-53F9F034B6EC Q35012881-A8A784E4-B7B3-4266-AC37-E5F1A59CF970 Q35054109-2C7D95DB-D1A9-43E2-868C-793C64C14888 Q35065863-75F3F505-1D89-4EAB-8656-7978E54800B2 Q35168993-9BD2DCB2-52D9-46CC-B18F-706E7AB13665 Q35191353-55F2D6FE-62AA-4EBD-9595-E343EE821EE7 Q35364351-487BCB3E-1BF5-431B-B19A-8AD874A067BA Q35432662-C80A9487-8D6E-45C5-8097-822ECF127786 Q35541277-BEF5A2AB-EE43-4149-9742-3EF710F6D9D7 Q35592264-DA97EAD0-FAA5-4580-82FF-75C949941396 Q35607925-F87D9D8A-0152-4DE6-8F17-B507ACC20A5C Q35662008-2D33ED52-2EE9-4182-8C35-DC7AEA63C87C Q35885209-20320FD3-5368-4B7C-BBDA-E915D514103E Q35941403-2F89FFEF-1D34-443C-A294-BCF6E0D70194 Q35977417-B82372E8-0AAC-49E3-B87C-E3DDA09D9891 Q36229076-94098D62-5DB5-4687-A674-E80C3DE8E13B Q36276852-D1BD76E0-9B72-47DF-9C07-D5280D305B62 Q36290642-1B01E3F8-A0E3-465F-919B-B32E812EB74E Q36299428-849F7C1B-5C94-4976-9446-43B7F473CBD4 Q36335694-2D18212A-5811-4F4F-BB38-50DB070809E8 Q36642374-0FAF7134-7B32-4688-A731-66905EFDDCDD Q36667079-1C4CF9B1-132D-4252-A4DD-227AF321EFA3 Q36730174-A571A62E-1ECA-4E08-8AE1-813F0DDCC1F9 Q36798184-A46F47EA-3C31-48AB-BCFB-2309FC094804

P2860

Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

http://www.wikidata.org/entity/Q39980070

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Nephrotoxicity associated with ...... tertiary care medical center.

@en

Nephrotoxicity associated with intravenous colistin

@nl

type

label

Nephrotoxicity associated with ...... tertiary care medical center.

@en

Nephrotoxicity associated with intravenous colistin

@nl

prefLabel

Nephrotoxicity associated with ...... tertiary care medical center.

@en

Nephrotoxicity associated with intravenous colistin

@nl

P1433

Q39980070-0CA3E05A-CEC1-48D3-B19A-553EA50A6C13

P1476

Q39980070-C534A99C-AA7C-42A4-8AE9-71EDE10AA763

P2093

Q39980070-521C6B1B-7B8F-427B-8A51-0EB7A408AF9A

Q39980070-564D88F1-85FD-4EEE-9A5B-F9CF783B7563

Q39980070-70866B0B-413D-4CA2-AF7A-43E3722D9A36

Q39980070-7A0011F6-D68D-47E0-9E73-C6643146616C

Q39980070-AB1FB30F-8226-408B-9905-C515954090DC

Q39980070-ABC68233-14AE-4210-BD26-6F1365D395D6

Q39980070-BCDB3F25-69D8-4B12-AD82-02433CAD6E9E

Q39980070-C1A6A204-E4A4-4705-BCD3-C334B75F31D0

Q39980070-FCE92C2C-4430-4278-9B3D-91D164275E61

P304

Q39980070-9CDB8C0F-FDC3-4182-9C5F-AFE00BAE6714

P31

Q39980070-D15851B6-E66B-4DF4-B95B-6190DC176649

P356

Q39980070-14779AE2-A483-4C36-905F-4290FAF1336F

P407

Q39980070-339FD0DB-2615-471B-A90A-ABDE519955C7

P433

Q39980070-629235FD-FC0F-4F96-983B-D91AAAECFE3B

P478

Q39980070-8B5E3E23-EE70-4E9B-ABEC-3681C16A9E6B

P577

Q39980070-E77105B7-EB45-4E27-85A0-C63B41F244F6

P5875

Q39980070-872EB3EA-737B-4861-93CD-51C3CF1EF297

P698

Q39980070-24D11D02-7CCC-4AE1-937C-CF39DC087A5D

P356

P1433

Clinical Infectious Diseases

P1476

Nephrotoxicity associated with ...... tertiary care medical center.

@en

P2093

Amy Weintrob

http://www.w3.org/2001/XMLSchema#string

Glenn Wortmann

http://www.w3.org/2001/XMLSchema#string

Joshua D Hartzell

http://www.w3.org/2001/XMLSchema#string

Julie Ake

http://www.w3.org/2001/XMLSchema#string

Kristopher Paolino

http://www.w3.org/2001/XMLSchema#string

Mark Vishnepolsky

http://www.w3.org/2001/XMLSchema#string

Robert Neff

http://www.w3.org/2001/XMLSchema#string

Robin Howard

http://www.w3.org/2001/XMLSchema#string

Stephen Olson

http://www.w3.org/2001/XMLSchema#string

P304

1724-1728

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/599225

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24423650

http://www.w3.org/2001/XMLSchema#string

P698

19438394

http://www.w3.org/2001/XMLSchema#string